Loading...
Market
How will Elevation Oncology's stock price change by end of 2024?
3
Resolution / Starting Odds
Decrease by more than 20% • 25%
Decrease by less than 20% • 25%
Increase by less than 20% • 25%
Increase by more than 20% • 25%
Stock price data from financial market sources like NASDAQ or Yahoo Finance
Story
Elevation Oncology Announces Promising Data from Phase 1 Trial for EO-3021 with 42.8% ORR and 71% DCR
Aug 6, 2024, 11:12 AM
Elevation Oncology has announced promising initial data from its Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2. The trial, which includes patients with gastric and gastroesophageal junction (GEJ) cancers, reported a confirmed overall response rate (ORR) of 42.8% and a disease control rate (DCR) of 71%. The study will now advance to the dose expansion phase. However, the stock price dropped by 40% following the release of the data, which showed an ORR of 20% in a subset of patients, significantly lower than the 47% observed in a previous Chinese study. The data indicated a higher ORR of 43% in patients with Claudin 18.2 expression greater than 20%, compared to the Chinese study's cutoff of greater than 1% expression.
View original story
Similar markets
Decrease by 5% or more • 25%
Change between -5% and 5% • 25%
Increase between 5% and 10% • 25%
Increase by 10% or more • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
No change or decrease • 25%
Decrease by more than 10% • 25%
Below $50 • 25%
$50-$100 • 25%
$100-$150 • 25%
Above $150 • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%